Abstract
Iron overload has been identified as important factor influencing the clinical course of patients with myelodysplastic syndromes. Chelating agents are available for the treatment of iron overload. Given the lack of data from prospective studies on the effects of iron chelation on the outcome of MDS patients, several guidelines for the use of chelators have been published. This article compares these guidelines and reviews the evidence for the recommendations.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
